| SC 13G | 2016-04-11 | WELLINGTON MANAGEMENT GROUP LLP | Affimed N.V. | 3,561,141 | 10.7% | EDGAR |
| SC 13D/A | 2016-03-31 | ORBIMED ADVISORS LLC | Affimed N.V. | 4,053,000 | 12.2% | EDGAR |
| SC 13D/A | 2016-03-17 | ORBIMED ADVISORS LLC | Affimed N.V. | 4,500,641 | 13.5% | EDGAR |
| SC 13G/A | 2016-02-12 | LSP III Omni Investment Cooperatief U.A. | Affimed N.V. | 1,493,199 | 4.5% | EDGAR |
| SC 13G/A | 2016-02-11 | WELLINGTON MANAGEMENT GROUP LLP | Affimed N.V. | 1,056,110 | 3.2% | EDGAR |
| SC 13G/A | 2016-01-21 | BioMedInvest I Ltd. | Affimed N.V. | 1,347,883 | 4.1% | EDGAR |
| SC 13D/A | 2015-12-17 | SGR Sagittarius Holding AG | Affimed N.V. | 8,939,924 | 26.9% | EDGAR |
| SC 13D/A | 2015-10-16 | SGR Sagittarius Holding AG | Affimed N.V. | 8,428,277 | 25.3% | EDGAR |
| SC 13D/A | 2015-08-17 | ORBIMED ADVISORS LLC | Affimed N.V. | 4,582,616 | 15.4% | EDGAR |
| SC 13D/A | 2015-05-27 | SGR Sagittarius Holding AG | Affimed N.V. | 5,334,397 | 17.9% | EDGAR |
| SC 13D/A | 2015-05-14 | ORBIMED ADVISORS LLC | Affimed N.V. | 5,814,630 | 19.6% | EDGAR |
| SC 13G | 2015-05-13 | Brookside Capital Trading Fund, L.P. | Affimed N.V. | 2,097,902 | 7.1% | EDGAR |
| SC 13D/A | 2015-02-24 | Technology Participation Co | Affimed N.V. | 300,400 | 1.3% | EDGAR |
| SC 13D/A | 2015-02-20 | ORBIMED ADVISORS LLC | Affimed N.V. | 5,814,630 | 24.2% | EDGAR |
| SC 13D/A | 2015-02-20 | KfW | Affimed N.V. | 335,276 | 1.4% | EDGAR |
| SC 13D/A | 2015-02-17 | SGR Sagittarius Holding AG | Affimed N.V. | 5,334,397 | 22.2% | EDGAR |
| SC 13G | 2015-02-17 | BioMedInvest I Ltd. | Affimed N.V. | 1,561,595 | 6.5% | EDGAR |
| SC 13G | 2015-02-17 | LSP III Omni Investment Cooperatief U.A. | Affimed N.V. | 1,561,403 | 6.5% | EDGAR |
| SC 13G | 2015-02-17 | Little Melvyn | Affimed N.V. | 151,080 | 0.6% | EDGAR |
| SC 13G | 2015-02-17 | German Cancer Research Center | Affimed N.V. | 28,001 | 0.1% | EDGAR |